A Phase 2 interventional study of Herceptin and Docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 77 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 45th largest by enrollment of the 366 interventional ones that give a count, is one of 18 that started in 2006, is one of 239 in phase 2, and was the 109th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 18 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 417 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 43rd largest by enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2006, is one of 65 in phase 2, and was the 30th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer. Before surgery, patients will be randomized to one of 4 treatment arms, to receive 4 cycles of a)Herceptin + docetaxel b)Herceptin + docetaxel + pertuzumab c)Herceptin + pertuzumab or 4)pertuzumab + docetaxel. Pertuzumab will be administered at a loading dose of 840mg iv, then 420mg iv 3-weekly, Herceptin at a loading dose of 8mg/kg iv then 6mg/kg 3-weekly, and docetaxel at a dose of 75mg/m2 escalating to 100mg/m2 3-weekly. During the entire pre- and post-surgery period all patients will receive adequate chemotherapy as per standard of care, as well as any surgery and/or radiotherapy as required. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Herceptin · Drug: Docetaxel
Drug: Herceptin · Drug: Docetaxel · Drug: Pertuzumab
Drug: Herceptin · Drug: Pertuzumab
Drug: Docetaxel · Drug: Pertuzumab
8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
Also known as: Trastuzumab
75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
840mg iv loading dose, followed by 420mg iv 3-weekly
Percentage of Participants Achieving Pathological Complete Response (pCR)
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders
Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Percentage of Participants Achieving pCR by Breast Cancer Type
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Based on the type of breast cancer participants were categorized as those with 1. Operable breast cancer, 2. Inflammatory breast cancer and 3. Locally advanced breast cancer. Participants with invalid/missing pCR assessments were defined as non-responders.
Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Percentage of Participants Achieving pCR by Hormone Receptor Status
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants were classified as Estrogen and/or Progesterone positive (+ve), Estrogen and/or Progesterone negative (-ve) or receptor status unknown. Participants with invalid/missing pCR assessments were defined as non-responders.
Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Percentage of Participants Achieving pCR by Lymph Node Status
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Lymph node status was defined as either negative lymph node at surgery or positive lymph node at surgery. Participants with invalid/missing pCR assessments were defined as non-responders.
Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Percentage of Participants Achieving pCR by Presence or Absence of Residual Intraductal Carcinoma (DCIS) / Intalobular Carcinoma (LCIS)
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders.
Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Percentage of Participants Achieving Best Primary Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Disease Progression [PD]) During Neo-Adjuvant Treatment by X-Ray/Mammography
Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is greater than (\>)0 at screening or cycle 1 Day 1; PR: if measurement is at least a 30 percent (%) decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline.
Time frame: Baseline up to Cycle 4 (assessed at, Baseline and Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During Neo-Adjuvant Period by X-Ray/Mammography
Tumor assessments were made based on the RECIST criteria - version 1.0 The overall response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Percentage of Participants Achieving Best Primary Breast Tumor Response (CR, PR, SD or PD) During Neo-Adjuvant Period by Clinical Examination
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During the Neo-Adjuvant Period by Clinical Examination
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by X-Ray/Mammography
Clinical response was determined based on tumor measurements by sponsor in combination with tumor response assessment by investigator. Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by Clinical Examination
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Primary breast tumor clinical response is based on primary breast tumor assessment. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Time to Clinical Response During Neo-Adjuvant Treatment Period
Time to clinical response was defined as the time from the date of first dose received to the date of assessment of clinical response. Time to Clinical response was determined by Kaplan-Meier estimates. Tumor assessments were made based on the RECIST criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment.
Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Percentage of Participants With Progressive Disease During Neo-Adjuvant Treatment Period
Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: PD: if lesion is at least a 20 % increased from measurements at baseline. Percentage of participants along with 95% Confidence Interval (CI) for one sample binomial using Pearson-Clopper method were reported. Missing investigator assessments were considered as no progressive disease.
Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Percentage of Participants Achieving Breast Conserving Surgery For Whom Mastectomy Was Planned
Breast Conserving Surgery (BCS) was defined as quadrantectomy, lumpectomy, no surgery, sentinel node biopsy, axillary surgical resection or other method of avoiding mastectomy.
Time frame: Surgery (Within 2 weeks after Cycle 4) Up to approximately 24 months
Percentage of Participants Who Were Progression Free and Disease Free
Disease-free survival (DFS) was defined as the time from first date of no disease to first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from the study without documented progression and for whom evaluations were made, were censored at date of last assessment when participant was known to be disease-free. Progression-free survival (PFS) was defined as time from date of randomization to first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from study without documented progression and for whom evaluations were made, were censored at date of last assessment when the participant was known to be free from progressive disease. Participants without post baseline assessments but known to be alive were censored at the time of randomization.
Time frame: Randomization up to a maximum of 329 weeks
Progression Free and Disease Free Survival
DFS was defined as the time from the first date of no disease (date of surgery) to the first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. PFS was defined as the time from the date of randomization to the first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. DFS and PFS were determined using Kaplan-Meier estimates.
Time frame: Randomization up to a maximum of 329 weeks
A total of 107, 107, 107, and 96 participants (total 417) were randomized to Arms Trastuzumab plus (+) Docetaxel (T+ D) , Trastuzumab+Pertuzumab+Docetaxel (T+Ptz+D), Trastuzumab+Pertuzumab (T+Ptz), and Pertuzumab+Docetaxel (Ptz+D), respectively and were included in intent-to-treat population (as randomized).
| Milestone | Trastuzumab + Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Started | 107 | 107 | 108 | 94 |
| Completed | 103 | 102 | 94 | 88 |
| Not completed | 4 | 5 | 14 | 6 |
| Withdrew: Protocol violation | 1 | 2 | 1 | 1 |
| Withdrew: Refused treatment | 1 | 1 | 4 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 7 | 2 |
| Withdrew: Unknown reason | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 2 |
| Milestone | Trastuzumab + Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Started | 103 | 102 | 94 | 88 |
| Completed | 98 | 94 | 90 | 74 |
| Not completed | 5 | 8 | 4 | 14 |
| Withdrew: Disease progression | 3 | 3 | 0 | 7 |
| Withdrew: Refused treatment | 1 | 1 | 1 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 3 | 2 | 2 |
| Withdrew: Unknown reason | 0 | 1 | 0 | 0 |
| Milestone | Trastuzumab + Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Started | 98 | 102 | 98 | 87 |
| Completed | 77 | 83 | 78 | 60 |
| Not completed | 21 | 19 | 20 | 27 |
| Withdrew: Death | 4 | 2 | 2 | 6 |
| Withdrew: Disease progression | 6 | 5 | 9 | 9 |
| Withdrew: Refused treatment | 6 | 2 | 0 | 2 |
| Withdrew: Lost to follow-up | 3 | 3 | 3 | 1 |
| Withdrew: Unspecified reason | 2 | 5 | 6 | 8 |
| Withdrew: Violation of selection criteria at entry | 0 | 2 | 0 | 1 |
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Percentage of Participants Achieving Pathological Complete Response (pCR) | 29.0 (20.6 to 38.5) | 45.8 (36.1 to 55.7) | 16.8 (10.3 to 25.3) | 24.0 (15.8 to 33.7) |
Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is greater than (\>)0 at screening or cycle 1 Day 1; PR: if measurement is at least a 30 percent (%) decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| CR | 18.3 | 19.0 | 13.1 | 19.1 |
| PR | 49.3 | 46.6 | 36.1 | 46.8 |
| SD | 31.0 | 32.8 | 44.3 | 34.0 |
| PD | 1.4 | 1.7 | 6.6 | 0.0 |
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Based on the type of breast cancer participants were categorized as those with 1. Operable breast cancer, 2. Inflammatory breast cancer and 3. Locally advanced breast cancer. Participants with invalid/missing pCR assessments were defined as non-responders.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Operable Breast Cancer (n=64,65,65,60) | 23.4 (13.8 to 35.7) | 47.7 (35.1 to 60.5) | 16.9 (8.8 to 28.3) | 26.7 (16.1 to 39.7) |
| Inflammatory Breast Cancer (n=7,10,7,5) | 14.3 (0.4 to 57.9) | 40.0 (12.2 to 73.8) | 28.6 (3.7 to 71.0) | 40.0 (5.3 to 85.3) |
| Locally Advance Breast Cancer (36,32,35,31) | 41.7 (25.5 to 59.2) | 43.8 (26.4 to 62.3) | 14.3 (4.8 to 30.3) | 16.1 (5.5 to 33.7) |
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants were classified as Estrogen and/or Progesterone positive (+ve), Estrogen and/or Progesterone negative (-ve) or receptor status unknown. Participants with invalid/missing pCR assessments were defined as non-responders.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Estrogen and/or Progesterone +ve (n=50,50,51,46) | 20.0 (10.0 to 33.7) | 26.0 (14.6 to 40.3) | 5.9 (1.2 to 16.2) | 17.4 (7.8 to 31.4) |
| Estrogen and/or Progesterone -ve (n=57,57,55,50) | 36.8 (24.4 to 50.7) | 63.2 (49.3 to 75.6) | 27.3 (16.1 to 41.0) | 30.0 (17.9 to 44.6) |
| Receptor Status Unknown (0,0,1,0) | NA (NA to NA) | NA (NA to NA) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Lymph node status was defined as either negative lymph node at surgery or positive lymph node at surgery. Participants with invalid/missing pCR assessments were defined as non-responders.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| pCR achieved and Negative Lymph Nodes at Surgery | 21.5 | 39.3 | 11.2 | 17.7 |
| pCR achieved and Positive Lymph Nodes at Surgery | 7.5 | 6.5 | 5.6 | 6.3 |
pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| pCR Achieved and No residual DCIS/LCIS at Surgery | 16.8 | 36.4 | 9.3 | 17.7 |
| pCR Achieved and Residual DCIS/LCIS at Surgery | 12.1 | 9.3 | 7.5 | 6.3 |
Tumor assessments were made based on the RECIST criteria - version 1.0 The overall response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| CR | 18.3 | 18.9 | 12.7 | 18.6 |
| PR | 49.3 | 49.1 | 34.5 | 46.5 |
| SD | 31.0 | 30.2 | 45.5 | 34.9 |
| PD | 1.4 | 1.9 | 7.3 | 0.0 |
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| CR | 23.2 | 30.7 | 16.7 | 20.9 |
| PR | 56.6 | 57.4 | 51.0 | 50.5 |
| SD | 20.2 | 11.9 | 30.4 | 28.6 |
| PD | 0.0 | 0.0 | 2.0 | 0.0 |
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| CR | 21.6 | 25.0 | 11.2 | 15.9 |
| PR | 59.8 | 63.0 | 55.1 | 58.0 |
| SD | 17.5 | 12.0 | 31.6 | 26.1 |
| PD | 1.0 | 0.0 | 2.0 | 0.0 |
Clinical response was determined based on tumor measurements by sponsor in combination with tumor response assessment by investigator. Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Overall response is derived based on the sum total of breast tumors and all nodes examined.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Primary Breast Tumor (n=71,58,61,47) | 67.6 (55.5 to 78.2) | 65.5 (51.9 to 77.5) | 49.2 (36.1 to 62.3) | 66.0 (50.7 to 79.1) |
| Overall Response (n=71,53,55,43) | 67.6 (55.5 to 78.2) | 67.9 (53.7 to 80.1) | 47.3 (33.7 to 61.2) | 65.1 (49.1 to 79.0) |
Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Primary breast tumor clinical response is based on primary breast tumor assessment. Overall response is derived based on the sum total of breast tumors and all nodes examined.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Primary Breast Tumor (n=99,101,102,91) | 79.8 (70.5 to 87.2) | 88.1 (80.2 to 93.7) | 67.6 (57.7 to 76.6) | 71.4 (61.0 to 80.4) |
| Overall Response (n=97,100,98,88) | 81.4 (72.3 to 88.6) | 88.0 (80.0 to 93.6) | 66.3 (56.1 to 75.6) | 73.9 (63.4 to 82.7) |
Time to clinical response was defined as the time from the date of first dose received to the date of assessment of clinical response. Time to Clinical response was determined by Kaplan-Meier estimates. Tumor assessments were made based on the RECIST criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment.
| months | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Time to Clinical Response During Neo-Adjuvant Treatment Period | 6.3 (6.0 to 7.0) | 6.3 (4.0 to 7.0) | 6.9 (6.0 to 9.0) | 7.3 (6.0 to 9.0) |
Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: PD: if lesion is at least a 20 % increased from measurements at baseline. Percentage of participants along with 95% Confidence Interval (CI) for one sample binomial using Pearson-Clopper method were reported. Missing investigator assessments were considered as no progressive disease.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Percentage of Participants With Progressive Disease During Neo-Adjuvant Treatment Period | 0.0 (0.0 to 3.4) | 0.9 (0.0 to 5.1) | 7.5 (3.3 to 14.2) | 2.1 (0.3 to 7.3) |
Breast Conserving Surgery (BCS) was defined as quadrantectomy, lumpectomy, no surgery, sentinel node biopsy, axillary surgical resection or other method of avoiding mastectomy.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Percentage of Participants Achieving Breast Conserving Surgery For Whom Mastectomy Was Planned | 22.6 (12.9 to 35.0) | 23.2 (13.0 to 36.4) | 18.0 (9.4 to 30.0) | 31.7 (20.3 to 45.0) |
Disease-free survival (DFS) was defined as the time from first date of no disease to first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from the study without documented progression and for whom evaluations were made, were censored at date of last assessment when participant was known to be disease-free. Progression-free survival (PFS) was defined as time from date of randomization to first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from study without documented progression and for whom evaluations were made, were censored at date of last assessment when the participant was known to be free from progressive disease. Participants without post baseline assessments but known to be alive were censored at the time of randomization.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Progression Free | 82.2 | 84.1 | 74.8 | 75.0 |
| Disease Free | 82.5 | 85.1 | 80.2 | 76.1 |
DFS was defined as the time from the first date of no disease (date of surgery) to the first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. PFS was defined as the time from the date of randomization to the first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. DFS and PFS were determined using Kaplan-Meier estimates.
| percentage of participants | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| PFS | NA (NA to NA) | 71.0 (71.0 to 76.0) | NA (NA to NA) | NA (NA to NA) |
| DFS | NA (NA to NA) | 67.2 (67.0 to 72.0) | NA (NA to NA) | NA (NA to NA) |
Collected over Adverse events were recorded from the date of Screening until the clinical cut off date 20th October 2014 up to 7 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab+Docetaxel | — | 21/107 (19.6%) | 107/107 (100%) |
| Trastuzumab+Pertuzumab+Docetaxel | — | 22/107 (20.6%) | 105/107 (98.1%) |
| Trastuzumab+Pertuzumab | — | 19/108 (17.6%) | 101/108 (93.5%) |
| Pertuzumab+Docetaxel | — | 21/94 (22.3%) | 94/94 (100%) |
| Event | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 10/107 | 8/107 | 4/108 | 12/94 |
| NeutropeniaBlood and lymphatic system disorders | 1/107 | 6/107 | 3/108 | 6/94 |
| Left ventricular dysfunctionCardiac disorders | 0/107 | 3/107 | 0/108 | 0/94 |
| Pyelonephritis acuteInfections and infestations | 0/107 | 2/107 | 0/108 | 0/94 |
| Wound infectionInfections and infestations | 2/107 | 0/107 | 0/108 | 0/94 |
| DiarrhoeaGastrointestinal disorders | 2/107 | 0/107 | 0/108 | 1/94 |
| PyrexiaGeneral disorders | 1/107 | 1/107 | 2/108 | 1/94 |
| CellulitisInfections and infestations | 0/107 | 0/107 | 0/108 | 1/94 |
| SepsisInfections and infestations | 0/107 | 0/107 | 0/108 | 1/94 |
| Staphylococcal sepsisInfections and infestations | 0/107 | 0/107 | 0/108 | 1/94 |
| Event | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 80/107 | 64/107 | 46/108 | 67/94 |
| AlopeciaSkin and subcutaneous tissue disorders | 75/107 | 73/107 | 59/108 | 65/94 |
| NauseaGastrointestinal disorders | 70/107 | 71/107 | 52/108 | 61/94 |
| DiarrhoeaGastrointestinal disorders | 40/107 | 55/107 | 46/108 | 52/94 |
| VomitingGastrointestinal disorders | 31/107 | 39/107 | 31/108 | 37/94 |
| FatigueGeneral disorders | 35/107 | 35/107 | 34/108 | 37/94 |
| RashSkin and subcutaneous tissue disorders | 26/107 | 30/107 | 22/108 | 30/94 |
| Mucosal inflammationGeneral disorders | 28/107 | 33/107 | 18/108 | 28/94 |
| General DisorderGeneral disorders | 17/107 | 16/107 | 15/108 | 26/94 |
| AstheniaGeneral disorders | 22/107 | 29/107 | 19/108 | 23/94 |
Intent-To-Treat (ITT) Population included all randomized participants who received any amount of study medication. Analysis was performed according to initial randomization.
| Age, Continuous(years) | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel | Total |
|---|---|---|---|---|---|
| Mean | 50.9 ± 8.94 | 49.6 ± 10.05 | 49.7 ± 10.67 | 48.9 ± 10.50 | 49.8 ± 10.04 |
| Sex: Female, Male(Participants) | Trastuzumab+Docetaxel | Trastuzumab+Pertuzumab+Docetaxel | Trastuzumab+Pertuzumab | Pertuzumab+Docetaxel | Total |
|---|---|---|---|---|---|
| Female | 107 | 107 | 107 | 96 | 417 |
| Male | 0 | 0 | 0 | 0 | 0 |
Ran from Jun 2006 to primary completion in Sep 2014, 98 months.
Results were first posted in Jan 2016, 1 year 4 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 98 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Trastuzumab · Docetaxel · Pertuzumab